Short-term rifampicin pretreatment reduces inflammation and neuronal cell death in a rabbit model of bacterial meningitis

Critical Care Medicine

Volumn 37, Issue 7, 2009, Pages 2253-2258

  Spreer, Annette ^a   Lugert, Raimond ^a   Stoltefaut, Valentin ^a   Hoecht, Anna ^a   Eiffert, Helmut ^a   Nau, Roland ^a,b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Sleep Laboratory   (Germany)

Author keywords

Meningeal inflammation; Meningitis; Neuronal apoptosis; Nonbacteriolytic antibiotics; Rabbit model; Streptococcus Pneumoniae

Indexed keywords

BACTERIAL DNA; CEFTRIAXONE; GLUCOSE; PNEUMOLYSIN; PROSTAGLANDIN E2; RIFAMPICIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; APOPTOSIS; ARTICLE; BACTERIAL COUNT; BACTERIUM CULTURE; CEREBROSPINAL FLUID LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EXPOSURE; EXPERIMENTAL RABBIT; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MONOTHERAPY; NERVE CELL NECROSIS; NONHUMAN; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SHORT COURSE THERAPY; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; ANIMAL; BACTERIAL MENINGITIS; CULTURE TECHNIQUE; DISEASE MODEL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; NERVE CELL; PATHOLOGY; RABBIT;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; CEFTRIAXONE; CELL CULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; MENINGITIS, PNEUMOCOCCAL; NEURONS; RABBITS; RIFAMPIN;

EID: 67649830264     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181a036c0     Document Type: Article

References (43)

1. Kastenbauer S, Pfister HW: Pneumococcal meningitis in adults: Spectrum of complications and prognostic factors in a series of 87 cases. Brain 2003; 126(Pt 5):1015-1025
2. Nau R, Brück W: Neuronal injury in bacterial meningitis: Mechanisms and implications for therapy. Trends Neurosci 2002; 25:38-45
3. Nau R, Eiffert H: Minimizing the release of proinflammatory and toxic bacterial products within the host: A promising approach to improve outcome in life-threatening infections. FEMS Immunol Med Microbiol 2005; 44:1-16
4. Spreer A, Gerber J, Baake D, et al: Antiinflammatory but no neuroprotective effects of melatonin under clinical treatment conditions in rabbit models of bacterial meningitis. J Neurosci Res 2006; 84:1575-1579
5. Zysk G, Brück W, Gerber J, et al: Antiinflammatory treatment influences neuronal apoptotic cell death in the dentate gyrus in experimental pneumococcal meningitis. J Neuropathol Exp Neurol 1996; 55:722-728
6. Nau R, Soto A, Brück W: Apoptosis of neurons in the dentate gyrus in humans suffering from bacterial meningitis. J Neuropathol Exp Neurol 1999; 58:265-274
7. Spreer A, Kerstan H, Bottcher T, et al: Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrob Agents Chemother 2003; 47:2649-2654
8. Klugman KP, Friedland IR, Bradley JS: Bactericidal activity against cephalosporinresistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995; 39:1988-1992
9. Nahata MC, Fan-Havard P, Barson WJ, et al: Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements. Eur J Clin Pharmacol 1990; 38:515-517
10. Greisen K, Loeffelholz M, Purohit A, et al: PCR primers and probes for the 16S rRNA gene of most species of pathogenic bacteria, including bacteria found in cerebrospinal fluid. J Clin Microbiol 1994; 32:335-351
11. Nau R, Prange HW, Menck S, et al: Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992; 29:719-724
12. Tunkel AR, Hartman BJ, Kaplan SL, et al: Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267-1284
13. Friedland IR, Paris M, Ehrett S, et al: Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993; 37: 1630-1636
14. Böttcher T, Ren H, Goiny M, et al: Clindamycin is neuroprotective in experimental Streptococcus pneumoniae meningitis compared with ceftriaxone. J Neurochem 2004; 91:1450-1460
15. de Gans J, van de Beek D: Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549-1556
16. Peltola H, Roine I, Fernandez J, et al: Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: A prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2007; 45:1277-1286
17. Spreer A, Gerber J, Hanssen M, et al: Dexamethasone increases hippocampal neuronal apoptosis in a rabbit model of Escherichia coli meningitis. Pediatr Res 2006; 60: 210-215
18. Leib SL, Heimgartner C, Bifrare YD, et al: Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr Res 2003; 54:353-357
19. Keenan PA, Jacobson MW, Soleymani RM, et al: The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 1996; 47:1396-1402
20. Yeh TF, Lin YJ, Lin HC, et al: Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004; 350:1304-1313
21. Gross SJ, Anbar RD, Mettelman BB: Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics 2005; 115:681-687
22. Weber JR, Tuomanen EI: Cellular damage in bacterial meningitis: An interplay of bacterial and host driven toxicity. J Neuroimmunol 2007; 184:45-52
23. Braun JS, Sublett JE, Freyer D, et al: Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis. J Clin Invest 2002; 109:19-27
24. Stringaris AK, Geisenhainer J, Bergmann F, et al: Neurotoxicity of pneumolysin, a major pneumococcal virulence factor, involves calcium influx and depends on activation of p38 mitogen-activated protein kinase. Neurobiol Dis 2002; 11:355-368
25. Iliev AI, Stringaris AK, Nau R, et al: Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9). FASEB J 2004; 18: 412-414
26. Schneider O, Michel U, Zysk G, et al: Clinical outcome in pneumococcal meningitis correlates with CSF lipoteichoic acid concentrations. Neurology 1999; 53:1584-1587
27. Arditi M, Ables L, Yogev R: Cerebrospinal fluid endotoxin levels in children with H. influenzae meningitis before and after administration of intravenous ceftriaxone. J Infect Dis 1989; 160:1005-1011
28. Eisenhut M, Meehan T, Batchelor L: Cerebrospinal fluid glucose levels and sensorineural hearing loss in bacterial meningitis. Infection 2003; 31:247-250
29. Sorensen HT, Nielsen GL, Schonheyder HC, et al: Outcome of pre-hospital antibiotic treatment of meningococcal disease. J Clin Epidemiol 1998; 51:717-721
30. Harnden A, Ninis N, Thompson M, et al: Parenteral penicillin for children with meningococcal disease before hospital admission: Case-control study. BMJ 2006; 332: 1295-1298
31. Orman KL, English BK: Effects of antibiotic class on the macrophage inflammatory response to Streptococcus pneumoniae. J Infect Dis 2000; 182:1561-1565
32. Nau R, Wellmer A, Soto A, et al: Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis. J Infect Dis 1999; 179:1557-1560
33. Friedland IR, Jafari H, Ehrett S, et al: Comparison of endotoxin release by different antimicrobial agents and the effect on inflammation in experimental Escherichia coli meningitis. J Infect Dis 1993; 168:657-662
34. Azeh I, Gerber J, Wellmer A, et al: Protein synthesis inhibiting clindamycin improves outcome in a mouse model of Staphylococcus aureus sepsis compared with the cell wall active ceftriaxone. Crit Care Med 2002; 30: 1560-1564
35. Böttcher T, Gerber J, Wellmer A, et al: Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis. J Infect Dis 2000; 181:2095-2098
36. Grandgirard D, Schurch C, Cottagnoud P, et al: Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2007; 51:2173-2178
37. Meli DN, Coimbra RS, Erhart DG, et al: Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis. Infect Immun 2006; 74:3890-3896
38. Weisfelt M, de Gans J, van der Poll T, et al: Pneumococcal meningitis in adults: New approaches to management and prevention. Lancet Neurol 2006; 5:332-342
39. Hof H: Listeriosis: Therapeutic options. FEMS Immunol Med Microbiol 2003; 35: 203-205
40. Stille W, Brodt H-R, Groll A, et al: Antibiotika-Therapie. Eleventh Edition. Stuttgard, Germany: Schattauer GmbH, 2005
41. Yogev R, Guzman-Cottrill J: Bacterial meningitis in children: Critical review of current concepts. Drugs 2005; 65:1097-1112
42. Proulx N, Frechette D, Toye B, et al: Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM 2005; 98:291-298
43. Gerber J, Pohl K, Sander V, et al: Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone. Antimicrob Agents Chemother 2003; 47:1313-1317